Abstract: The invention relates to agents for the control of parasites on animals, comprising an active substance from the group of the phenylpyrazoles and vitamin E or a derivative thereof, such as particularly vitamin E acetate, as well as optionally a further active substance from the group of the pyrethroids and/or optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such agents for the control of ectoparasites such as, in particular, fleas, ticks and sand flies in pets such as, in particular, in dogs, cats and ferrets.

Abstract: The present invention relates to novel isocyanate and isothiocyanate compounds, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans and animals. The novel isocyanate and isothiocyanate compounds are distinguished, as compared with the known isocyanate and isothiocyanate compounds, by improved therapeutical breadth, i.e. fewer side effects while having high anti-tumor activity.

Abstract: The invention relates to agents for the control of parasites on animals, comprising an active substance from the group of the phenylpyrazoles and vitamin E or a derivative thereof, such as particularly vitamin E acetate, as well as optionally a further active substance from the group of the pyrethroids and/or optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such agents for the control of ectoparasites such as, in particular, fleas, ticks and sand flies in pets such as, in particular, in dogs, cats and ferrets.

Abstract: The present invention relates to novel isocyanate and isothiocyanate compounds, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans and animals. The novel isocyanate and isothiocyanate compounds are distinguished, as compared with the known isocyanate and isothiocyanate compounds, by improved therapeutical breadth, i.e. fewer side effects while having high anti-tumor activity.

Abstract: The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects.

Abstract: The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects.

Abstract: The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects.

Abstract: The present invention relates to pharmaceutical presentations for animals which are administered orally and which are accepted readily by the animals (for example dogs, cats and horses), to processes for their preparation and to their use, in particular as endoparasiticides.

Abstract: The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects.

Abstract: The invention relates to the use of certain cyclic acetals or ketals for improving the penetration of pharmaceutical agents into cells and organs.

Abstract: The invention relates to the use of certain cyclic acetals or ketals for improving the penetration of pharmaceutical agents into cells and organs.

Abstract: The present invention relates to compositions containing different stages of pathogenic protozoans in a gel and to their use for controlling rodents.

Abstract: The invention relates to a combination of radio waves with pharmacologically active substances chosen from the group: a) monoclonal antibodies and/or b) tyrosine-kinase inhibitors and/or c) angiogenesis inhibitors and/or d) farnesyl-transferase inhibitors and/or e) topoisomerase-I or -II inhibitors and/or f) cytokines and/or g) antisense oligonucleotides. optionally together with one or more chemotherapeutics, as well as to the use of this combination for the prophylaxis and/or treatment of cancer, tumors and metastases.

Abstract: The invention concerns stents containing compounds of formula (I) and methods for making said stents as well as their use.

Abstract: The application relates to vitronectin receptor antagonist-containing stents and to their production and use.

Abstract: The invention relates to the use of crystal form (I) of the cyclic depsipeptide of the formula (I) for preparing medicaments, in particular for controlling endoparasites.

Abstract: The present invention relates to pharmaceutical presentations for animals which are administered orally and which are accepted readily by the animals (for example dogs, cats and horses), to processes for their preparation and to their use, in particular as endoparasiticides.

Abstract: The present invention relates to compositions containing different stages of pathogenic protozoans in a gel and to their use for controlling rodents.

Abstract: The present invention provides topically administrable endoparasiticidal compositions comprising cyclic and open-chain depsipeptides consisting of amino acid and hydroxycarboxylic acid building blocks and containing 6 to 30 ring or chain atoms, their preparation and their use as endoparasiticides.

Abstract: The present invention relates to immediately acting pest control compositions based on cyclic polysiloxanes, which can be employed without a residue and without a lasting action.